Latest Conference Articles

Kyle McCormick, PharmD, owner of Blueberry Pharmacy, discusses the differences between a traditional pharmacy model and a cost-plus pharmacy model.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

Tripp Logan, PharmD, vice president at SEMO Rx Pharmacies and Logan & Seiler Inc discusses how pharmacy staff and community health care workers can work together to address social determinants of health.

Bri Morris, PharmD, senior director of Education and the Long-Term Care Division at the National Community Pharmacists Association, discusses the importance of teamwork in the pharmacy.

Motivational interviewing is an evidence-based method of communicating with patients who are ambivalent or resistant to change for the sake of their health.

The value proposition for point-of-care testing in the pharmacy is extensive, as pharmacies can provide a convenient, accessible, and cost-saving alternative for patients.

Mosunetuzumab showed promising results in complete response rate in patients with follicular lymphoma.

Ronna Hauser, PharmD, and Bri Morris, PharmD, both from the National Community Pharmacists Association, discuss long-term care facilities and how they can make an impact on that patient population.

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

Douglas Hoey, CEO of NCPA, discusses NCPA's Annual Convention 2022, which will be held in Kansas City, Missouri from October 1 to October 4.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.

Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.

Despite significant advances in cancer treatment, molecular sequencing and enrollment of Black patients in clinical trials are still less than that of White and Asian patients.

Yvonne Chen, PhD, discusses her research to engineer more safe and effective next-generation CAR-T therapy for cancer immunotherapy.

IDH inhibitors show encouraging results in patients with myelodysplastic syndrome, but longer follow ups are needed in a larger patient population to confirm the results.

Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.

New research has shown significant promise for the use of CAR T-cell therapies in solid tumors.

The All of Us Research Program looks to enroll more than 1 million US individuals in the next 10 years to enable public access to medical data for research purposes.

Data showed that Black women, regardless of education level or income, are more likely to reside in disadvantaged neighborhoods, which may contribute to racial disparities in breast cancer.

Second- and third-generation individuals living in Los Angeles, California, demonstrate 35% and 61%, respectively, more of a chance of getting the disease, according to new study results.

Triplet combination demonstrates a reduction in the risk of disease progression or death in individuals with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.

New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.

Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

An estimated 31.4% of individuals with non-squamous non–small cell lung cancer treated with the combination were alive at 3 years compared to 17.3% for those on chemotherapy alone.